SVB Leerink Maintains Outperform on Agilon Health, Lowers Price Target to $35
SVB Leerink analyst Whit Mayo maintains Agilon Health (NYSE:AGL) with a Outperform and lowers the price target from $37 to $35.
Agilon Health Q3 Sales $459.00M Beat $450.35M Estimate
Agilon Health (NYSE:AGL) reported quarterly sales of $459.00 million which beat the analyst consensus estimate of $450.35 million by 1.92 percent.
Looking Into Agilon Health’s Return On Capital Employed
According to Benzinga Pro data, Agilon Health (NYSE:AGL) reported Q2 sales of $498.96 million. Earnings fell to a loss of $298.36 million, resulting in a 2362.76% decrease from last quarter.
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
Jefferies Initiates Coverage On Agilon Health with Buy Rating, Announces Price Target of $35
Jefferies analyst Brian Tanquilut initiates coverage on Agilon Health (NYSE:AGL) with a Buy rating and announces Price Target of $35.
SVB Leerink Initiates Coverage On Agilon Health with Outperform Rating, Announces Price Target of $37
SVB Leerink analyst Whit Mayo initiates coverage on Agilon Health (NYSE:AGL) with a Outperform rating and announces Price Target of $37.
Cowen & Co. Initiates Coverage On Agilon Health with Outperform Rating, Announces Price Target of $44
Cowen & Co. analyst Gary Taylor initiates coverage on Agilon Health (NYSE:AGL) with a Outperform rating and announces Price Target of $44.